Lanzul

Lansoprazole, the active ingredient in Lanzul, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces gastric acid secretion and is employed to manage conditions such as gastro‑oesophageal reflux disease, peptic ulcer disease, erosive esophagitis and as part of Helicobacter pylori eradication regimens.

GNH USA supplies Lanzul as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazole is indicated for acid‑related gastrointestinal disorders and works by suppressing gastric acid production. - Gastro‑esophageal reflux disease (GERD): decreases acid exposure, relieving heartburn and regurgitation. - Peptic ulcer disease: promotes ulcer healing by maintaining a higher gastric pH. - Helicobacter pylori eradication (in combination therapy): enhances the effectiveness of antibiotics by reducing gastric acidity. - Erosive esophagitis: facilitates mucosal healing and symptom improvement.

Adverse reactions may occur with lansoprazole therapy.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: watery stools, usually transient. - Nausea: occasional feeling of stomach upset. - Abdominal pain: cramping or discomfort. - Flatulence: increased gas production. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing. - Clostridioides difficile infection: persistent watery diarrhea. - Low magnesium levels: muscle cramps, irregular heartbeat. - Bone fractures: increased risk with long‑term use. - Liver enzyme elevation: jaundice or abnormal liver tests.

Before initiating lansoprazole, consider the following safety measures. - Assess renal function: adjust use in severe impairment. - Review hepatic status: caution in moderate to severe liver disease. - Evaluate for osteoporosis risk: long‑term therapy may affect bone density. - Monitor for infection: prolonged acid suppression can increase gastrointestinal infection risk. - Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Lansoprazole may alter the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Antifungal agents (e.g., ketoconazole, itraconazole): reduced absorption, may lose efficacy. - HIV protease inhibitors (e.g., atazanavir): decreased plasma levels, risk of therapeutic failure. - Clopidogrel: diminished activation, potentially lowering antiplatelet effect.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, monitor coagulation parameters. - Methotrexate (high dose): reduced clearance, watch for toxicity. - Digoxin: slight increase in serum concentration, consider dose adjustment. - Diazepam: modest rise in levels, observe for enhanced sedation.